CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 89 enrolled
Drug / intervention
NGM120 30mg +5 morebiological
Likely dose
NGM120 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04068896
NCT04068896Phase 2Completed
CompareCT.gov

A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

NGM Biopharmaceuticals, Inc·interventional·Posted Aug 28, 2019·Updated May 29, 2025

In Brief

A Phase 2 clinical trial evaluating NGM120 30mg, NGM120 100mg, and 4 other interventions for Pancreatic Cancer and 10 related conditions. Completed, enrolled 89 participants across 20 sites.

Detailed Summary

Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ovarian Cancer, Head Neck Squamous Cell Carcinoma, Prostate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 28, 2019
Enrollment StartOct 16, 2019
Primary CompletionSep 21, 2023
Study CompletionJan 8, 2024
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 6.8 years ago

Interventions

NGM120 30mgbiological

NGM120 30mg Subcutaneous Injection

NGM120 100mgbiological

NGM120 100mg Subcutaneous Injection

NGM120 30mg with Gemcitabine and Abraxanebiological

NGM120 30mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

NGM120 100mg with Gemcitabine and Abraxanebiological

NGM120 100 mg Subcutaneous Injection together with gemcitabine (1000 mg/m2 weekly for first 3 weeks of the 4-week cycle) and Abraxane (125 mg/m2 weekly for first 3 weeks of the 4-week cycle).

NGM120 100mg Q3Wbiological

NGM120 100mg Subcutaneous Injection every 3 weeks

Placeboother

Placebo